Biomarin Pharmaceutical Inc

US

BMRN

Health Care

89.49 ₽

Current price

Hold
89.49 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    272 / 1361

  • Position in country

    4943 / 14179

  • Return on Assets, %

    2.5

    -40.3

  • Net income margin, %

    3.1

    -180

  • EBITDA margin, %

    6.3

    -168.2

  • Debt to Equity, %

    21.9

    3.2

  • Intangible assets and goodwill, %

    7.1

    0.2

  • Revenue CAGR 3Y, %

    9.1

    12.5

  • Total Equity change 1Y, %

    7.5

    -9

  • Revenue Y, % chg

    15.4

    0

  • P/E

    105

    31

  • P/BV

    3.5

    1.8

  • P/S

    7.1

    10.3

  • EV/S

    7.1

    7.5

  • EV/EBITDA

    66.3

    -1.6

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    18.1

    131.1

  • Forward P/E

    46.8

    21.4

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Biomarin Pharmaceutical Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    17399.6

  • Ticker

    BMRN.O

  • ISIN

    US09061G1013

  • IPO date

    1999-07-23

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-26

  • Date fact. publication of reports

    2023-12-31

Company Description

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: